Entries by Louise Mason

Mission Therapeutics Presenting at The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference

Preclinical data will be presented on novel USP30 inhibitors being developed as potential therapies for Parkinson’s disease Program of research supported by grant from The Michael J. Fox Foundation for Parkinson’s Research CAMBRIDGE, UK – 30 October 2017 – Mission Therapeutics announced that its Medical Director, CNS Translational Medicine, Dr Paul Thompson will be delivering […]

Mission Therapeutics’ Scientists Highlight Significance of Deubiquitylating Enzymes (DUBs) as Key Drug Targets

Keynote Nature article reviews drug discovery opportunities in multiple disease areas of unmet need CAMBRIDGE, UK – 29 September 2017 – An article entitled “Deubiquitylating enzymes (DUBs) and drug discovery: emerging opportunities,” written by the drug discovery team at Mission Therapeutics was published online today in the scientific journal Nature Reviews Drug Discovery. The peer-reviewed […]